Eris Lifesciences · NSE: ERIS · BSE: 540596
Q3 FY21 results · Oct–Dec 2020
Eris Lifesciences reported revenue from operations of ₹310.42 crore (up 16.5% from Q3 FY20) and net profit of ₹90.15 crore (up 42.0% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 310.42 | 266.40 | +16.5% | 329.99 | −5.9% |
| Other income | 3.07 | 8.47 | −63.7% | 2.08 | +47.4% |
| Total income | 313.50 | 274.87 | +14.1% | 332.08 | −5.6% |
| Profit before tax | 99.30 | 72.16 | +37.6% | 115.84 | −14.3% |
| Net profit for the period | 90.15 | 63.47 | +42.0% | 107.72 | −16.3% |
| EPS, basic (₹) | 6.64 | 4.62 | +43.7% | 7.93 | −16.3% |
| Net margin (%) | 29.0 | 23.8 | 32.6 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 287.13 | 254.27 | +12.9% | 303.37 | −5.4% |
| Other income | 3.43 | 7.91 | −56.6% | 2.41 | +42.3% |
| Total income | 290.56 | 262.18 | +10.8% | 305.78 | −5.0% |
| Profit before tax | 97.37 | 71.01 | +37.1% | 112.94 | −13.8% |
| Net profit for the period | 88.63 | 62.68 | +41.4% | 105.49 | −16.0% |
| EPS, basic (₹) | 6.52 | 4.55 | +43.3% | 7.77 | −16.1% |
| Net margin (%) | 30.9 | 24.6 | 34.8 |
Consolidated
- Filed with BSE
- 28 Jan 2021, 18:05 IST
- Board meeting
- 28 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jan 2021, 18:05 IST
- Board meeting
- 28 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE